Document Type
Article
Publication Date
2016
Abstract
We have a limited arsenal with which to treat invasive fungal infections caused by Aspergillus and Mucorales. The morbidity and mortality for both pathogens remains high. A triazole antifungal, isavuconazole, was recently granted approval by the US Food and Drug Administration and the European Medicines Agency for the treatment of invasive aspergillosis and mucormycosis. A randomized double-blind comparison trial for the treatment of invasive aspergillosis found isavuconazole noninferior to voriconazole. A separate, open-label study evaluating the efficacy of isavuconazole in the treatment of mucormycosis found comparable response rates to amphotericin B and posaconazole treated historical controls. The prodrug isavuconazonium sulfate is commercially available in both an oral and intravenous formulation and is generally well tolerated. Isavuconazole’s broad spectrum of activity, limited side effect profile, and favorable pharmacokinetics will likely solidify its place in therapy.
Recommended Citation
Donnelley, M. A., Zhu, E. S., & Thompson, G. R., III. (2016). Isavuconazole in the treatment of invasive aspergillosis and mucormycosis infections. Infection and Drug Resistance, 9, 79-86.
Publisher's Statement
Originally published in Infection and Drug Resistance, 9, 79-86. Licensed under CC BY-NC 3.0. doi:10.2147/IDR.S81416
